The association between aging and cancer is complex. Recent studies have developed measures of biological aging based on DNA methylation and called them "age acceleration." We aimed to assess the associations of age acceleration with risk of and survival from seven common cancers. Seven case-control studies of DNA methylation and colorectal, gastric, kidney, lung, prostate and urothelial cancer and B-cell lymphoma nested in the Melbourne Collaborative Cohort Study were conducted. Cancer cases, vital status and cause of death were ascertained through linkage with cancer and death registries. Conditional logistic regression and Cox models were used to estimate odds ratios (OR) and hazard ratios (HR) and 95% confidence intervals (CI) for associations of five age acceleration measures derived from the Human Methylation 450 K Beadchip assay with cancer risk (N 5 3,216 cases) and survival (N 5 1,726 deaths), respectively. Epigenetic aging was associated with increased cancer risk, ranging from 4% to 9% per five-year age acceleration for the 5 measures considered. Heterogeneity by study was observed, with stronger associations for risk of kidney cancer and B-cell lymphoma. An associated increased risk of death following cancer diagnosis ranged from 2% to 6% per five-year age acceleration, with no evidence of heterogeneity by cancer site. Cancer risk and mortality were increased by 15-30% for the fourth versus first quartile of age acceleration. DNA methylation-based measures of biological aging are associated with increased cancer risk and shorter cancer survival, independently of major health risk factors.
Biological aging refers to the progressive deterioration of an organism's physiological integrity and function, eventually leading to death. 1 The rate of this process is variable between individuals and across generations. 2 Previous studies have generally reported that associations of biological age with cancer risk are weaker than those observed with other causes of death (e.g., cardiovascular disease). This has been reported for certain biomarkers of aging 3 and frailty indices.
DNA methylation varies substantially with age, with a decrease in methylation levels being observed globally. [12] [13] [14] These changes may be associated with the risk of disease, including cancer. [15] [16] [17] [18] Recent research has defined an "epigenetic clock" based on age-associated methylation changes. Most studies have modelled chronological age using regularized regression methods to obtain a restricted set of predictive DNA methylation measures. [19] [20] [21] [22] [23] Two of these models have received more attention in the recent literature as they more accurately predict chronological age. 19, 21 The difference between predicted age and chronological age has been named "age acceleration" and interpreted in recent epidemiological and clinical studies as a marker of biological aging. Several studies have assessed the association between age acceleration and mortality. [24] [25] [26] [27] Few studies have examined whether the epigenetic clock is associated with the risk of cancer. In a study based on 43 cases, the risk of lung cancer was increased by an estimated 50% per five-year age acceleration. 28 Another small study (132 cancer cases) concluded that age acceleration was associated with increased cancer risk and shorter cancer survival. 29 A recent study of 480 breast cancer cases and matched controls 30 reported a 4% increase breast cancer risk per one-year age acceleration. In another study, the magnitude of the association of age acceleration with death due to cancer was similar to estimates obtained for other causes of death. 25 We previously found that age acceleration was associated with all-cause mortality independently of major health risk factors. 27 In this study, we aimed to assess associations of age acceleration with cancer risk and survival. We used data from seven case-control studies nested in the Melbourne Collaborative Cohort Study (MCCS), including 3,216 incident cases (and matched controls), 1,726 of whom died during follow-up.
Material and Methods

Study sample and blood collection
We used data collected from participants in the MCCS, a prospective study of 41,513 healthy adult volunteers (24, 469 women) aged between 27 and 76 years (99.3% aged when recruited between 1990 and 1994. 31 DNA samples were collected from peripheral blood drawn at the time of recruitment (1990) (1991) (1992) (1993) (1994) or at the wave 2 follow-up visit (2003) (2004) (2005) (2006) (2007) . The DNA source was dried blood spots, peripheral blood mononuclear cells or buffy coats for 70%, 28% and 2% of participants, respectively (Supporting Information).
Study participants provided informed consent in accordance with the Declaration of Helsinki and the study was approved by Cancer Council Victoria's Human Research Ethics Committee.
Cancer and death ascertainment
A series of case-control studies nested within the MCCS of breast, colorectal, gastric, kidney, lung, mature B-cell lymphoma, prostate and urothelial cancer were conducted. [32] [33] [34] [35] Cancer diagnoses were identified by linkage with the Victorian Cancer Registry and the Australian Cancer Database (Australian Institute of Health and Welfare). For each nested casecontrol study, controls were individually matched to incident cases (diagnosed after blood sample collection) on age using incidence density sampling (i.e. they had to be free of the cancer of interest up to the age at diagnosis of the corresponding case), sex, country of birth (Australia/New-Zealand, Southern Europe, Northern Europe), blood DNA source (dried blood spots, peripheral blood mononuclear cells or buffy coat) and collection period (baseline or wave 2). Controls were also matched to cases on year of birth, except for the colorectal cancer study where controls were matched on year of baseline attendance. For the lung cancer study, controls were also matched on smoking status at the time of blood collection. Vital status to 30 November 2015 was ascertained through record linkage to the Victorian Registry of Births, Deaths and Marriages and the National Death Index. Cause of death was known for 98.4% of deaths occurring up to 31 December 2013, and classified as "other cause" when missing.
DNA extraction and bisulfite conversion, and DNA methylation data processing Methods relating to DNA extraction and bisulfite conversion, and DNA methylation data processing have been described previously [32] [33] [34] [35] [36] [37] and are detailed in Supporting Information.
Methylation age and age acceleration
We used the Hannum and Horvath methods to determine methylation age and age acceleration, as these have consistently been shown to be the most accurate predictors of chronological age. 24, 25, 38, 39 Hannum methylation age was computed using a linear combination of methylation measures at 71 ageassociated CpGs. 24 Horvath methylation age uses a set of methylation measures at 353 CpGs and was computed using the online calculator. 21 The CpGs used by the two predictors
What's new?
Aging is associated with profound changes in DNA methylation levels. These can be used to build accurate age predictors ("epigenetic clocks") that deviate from chronological age by only a few years, a phenomenon named "age acceleration". In this study of seven types of cancer, the authors found that age acceleration was associated with both increased cancer risk and decreased cancer survival, independently of major health risk factors. These results support the usefulness of methylation markers of biological aging as a tool to predict health outcomes and may provide valuable insight into the relationship between aging and cancer.
do not overlap and were all available in our study after quality control. Estimates of cell type composition of blood were obtained using the Houseman algorithm. 40, 41 We considered the following most recent measures of age acceleration 26, 42 : (i) epigenetic age acceleration (AA) based on the residuals from a linear regression of Horvath's estimate of epigenetic age on chronological age, referred to as AA-Horvath, (ii) the corresponding measure based on Hannum (AA-Hannum), (iii) intrinsic epigenetic age acceleration based on the residuals resulting from a linear regression of Horvath's estimate of epigenetic age on chronological age and measures of blood cell counts, referred to as IEAA-Horvath, (iv) the corresponding measure based on Hannum (IEAA-Hannum), (v) enhanced Hannum age acceleration (EEAA), defined as AA-Hannum plus a weighted average of age-associated cell counts. 26 
Statistical analysis
Correlations between age acceleration measures were assessed by calculating Spearman correlation coefficients. Missing covariate data (<1% for any individual covariate) were handled using multiple imputation with the R package mice.
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The reliability of the five age acceleration measures was examined using intraclass correlation coefficients, based on 127 technical replicates, following the method described previously. 37 Relative risk estimates were calculated per five-year increment of age acceleration. 24, 25, 38 Quartiles of age acceleration measures were based on the distribution in controls. We used conditional logistic regression to estimate odds ratios (ORs) for the associations between age acceleration and the risk of cancer. In Model 1, no covariates were included. In Model 2, we adjusted for smoking (never, former: quit 15 years prior, former: quit >15 years prior, current 20 cigarettes per day, current >20 cigarettes per day), body-mass index (<25, [25] [26] [27] [28] [29] [30] [30] [31] [32] [33] [34] [35] and education (score from 1 to 8, 1: primary school only and 8: tertiary university degree or more). These models were used to analyze each cancer site separately, and all seven cancers combined. For the combined analysis, where an individual was diagnosed with several cancers, we included the first diagnosis only (respecting the incidence density sampling procedure), so that participants did not contribute twice to the pooled estimates. Heterogeneity in the associations by study was assessed by comparing models with and without an interaction term between age acceleration measure and casecontrol study, using a likelihood ratio test. We tested for linear trends in the ORs by attained age, age at blood draw and time since blood draw by including in the models pseudocontinuous versions of these (median value of each category) and their interaction with age acceleration measures.
We used Cox models to estimate hazard ratios (HRs) for the association between age acceleration and the risk of death following cancer diagnosis. This analysis was thus restricted to cancer cases. Time since diagnosis was used as the timescale, and person-years of follow-up were calculated from the diagnosis date until the date of death, and censored at the date of departure from Australia or end of follow-up (30 November 2015 for all-cause death and 31 December 2013 for causespecific death), whichever came first. The proportional hazards assumption was assessed by visual inspection of Schoenfeld residuals. 47 Separate models were fitted for all-cause mortality, and for death due to cancer or another cause. Covariates included in the analysis were the same as those described above for cancer risk, plus age, sex, country of birth, sample type and plate, the latter fitted as a fixed effect. For the analysis of all cancers combined, cancer site was included as a stratification variable, thereby allowing the underlying hazard function to vary by cancer site. 48 Where an individual was diagnosed with several cancers, only the first diagnosis was included. Heterogeneity in the HRs by cancer site and tests for trend in the HRs by age at diagnosis, time between blood draw and diagnosis and time since diagnosis were calculated using the same methodology as for the cancer risk analysis.
Results
The correlations of the Horvath and Hannum age predictors with chronological age were q 5 0.73 and q 5 0.78, respectively. The median age acceleration was, in absolute terms, 3.8 years for Horvath and 3.4 years for Hannum. The correlation between AA-Horvath and AA-Hannum was q 5 0.49; the correlation between IEAA-Horvath and IEAA-Hannum was q 5 0.45 (Table 1 and Supporting Information, Figs. 1 and 2). The reliability of age acceleration measures ranged from 0.64 to 0.77 (Table 1) . Matching variables and other participant characteristics for each nested case-control study are presented in Supporting Information, Table 1 .
For all measures, ORs for cancer risk were greater than one for most cancer types (Table 2) . Some evidence of heterogeneity was observed by study for AA-Hannum and EEAA (p 5 0.03 and 0.001, respectively). OR estimates were greatest for kidney cancer (AA-Hannum: OR 5 1.46, 95%CI: 1.10-1.94, Model 2). Higher ORs were also observed for B-cell lymphomas (AA-Horvath: OR 5 1.16, 95%CI: 1.05-1.27, AA-Hannum: OR 5 1.22, 95%CI: 1.09-1.38, EEAA: OR 5 1.27, 95%CI: 1.14-1.41). Results were similar for Model 1 and Model 2, indicating that lifestyle and socioeconomic variables had little confounding effect on the observed associations. ORs for all cancers combined showed risk increases ranging from 4% to 9% per fiveyear age acceleration (Model 2: IEAA-Horvath: OR 5 1.04, 95%CI: 1.00-1.09; AA-Hannum: OR 5 1.09, 95%CI: 1.04-1.14), Table 2 . For all five predictors, the risk of cancer was approximately 20% higher for the highest versus lowest quartile of age acceleration (Fig. 1) . Stronger associations were observed at
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younger ages, particularly for AA-Hannum (before age 60 years: OR 5 1.28, 95%CI: 1.11-1.47), but no consistent trend in the HRs was observed, as was the case for age at blood draw and time since blood draw (Table 3) .
A total of 1,726 deaths were observed during follow-up (median follow-up time 5 8. Table 4 . Mortality was 10% to 30% higher for the highest versus lowest quartile of age acceleration (Fig. 1) . A total of 1,580 deaths, diagnosed up to 31 December 2013, were included in the cause-specific mortality analysis, 1,271 deaths being due to cancer and 309 due to another cause (cardiovascular deaths, N 5 185). The HRs did not appear to vary substantially by cause of death (p heterogeneity 0.08, Table 4 ). Consistent results were observed for all cancers individually, with no evidence of heterogeneity by cancer site (p > 0.38, Supporting Information, Table 2 ). HR estimates suggested stronger associations were also observed for cases diagnosed less than five years after blood draw but no trend was observed (Supporting Information, Table 3 ). 
Discussion
The measures of biological aging we considered, derived from DNA methylation in blood, 49, 50 were associated with increased cancer risk and shorter cancer survival after adjustment for major health risk factors. Although there was some evidence that the association with cancer risk varied by study for Hannum age acceleration, there was no evidence of heterogeneity for other age acceleration measures or for cancer survival. These associations were largely consistent across cancer types. Relative risks were not substantially changed after adjustment for major health risk factors and for blood cell composition (via the "intrinsic" measures), which suggests that confounding is unlikely to fully explain the observed associations. As in previous studies, 26, 27 we observed consistently stronger associations with both cancer risk and survival for measures derived from the Hannum predictor, which was validated using blood samples. Therefore, although measures derived from the Horvath predictor may be more generalizable because they have been validated across multiple tissue types, 21 our findings indicate that a predictor validated on the tissue on which it is used might be preferable. Additionally, the relatively stronger associations we observed with risk of B-cell lymphoma suggests that the tissue in which age acceleration is measured may be important: while the risk was more strongly increased for measures that were not independent of cell composition (by 16%, 22% and 27% for AA-Horvath, AA-Hannum and EEAA, respectively), these associations were still apparent when using intrinsic measures (risk increased by 9%
and 15% for IEAA-Horvath and IEAA-Hannum, respectively). Only blood samples were available in our study, so we could not compare our measures with age acceleration in other tissues relevant to each cancer type (e.g., prostate tissue to study prostate cancer). The stronger associations observed for kidney cancer were based on a relatively small sample size, so they should be interpreted with caution. The main strength of our study is its prospective design, particularly for the assessment of associations with cancer risk. All blood samples were obtained from participants prior to cancer diagnosis. Measures of DNA methylation in retrospective studies may reflect molecular changes due to carcinogenesis and treatment. Another strength of our study is that cases and controls were matched on several relevant variables including age, sex and country of birth, with additional adjustment for several potential confounding factors. Further, case-control pairs were placed on a same Beadchip assay, thereby minimizing potential batch effects. 51 Finally, we assessed separately associations with cancer incidence and survival, which was not done by previous studies of cancer mortality. The main limitation of our study relates to the assessment of cancer survival, as blood samples for many cases were collected well before diagnosis. Nevertheless, the assumption that age acceleration does not vary to a great extent in middle-aged and older adults is perhaps not unreasonable, as shown in a previous study, 52 and because most dramatic changes to DNA methylation occur in early life through to adolescence. 12, 53, 54 Furthermore, associations with cancer survival appeared to be strongest when restricted to cases diagnosed within five years of blood draw, so that our study might provide conservative estimates of association with overall cancer survival. Finally, we did not formally adjust our results for multiple testing because tests were largely nonindependent in our study; however, the vast majority of relative risk estimates were in the direction we had hypothesized, and their magnitude was consistent with prior studies. While several studies have assessed the association of age acceleration with mortality, [24] [25] [26] [27] 38 there have been fewer analy- 25 This is in contrast to our study, where we observed stronger associations for IEAA-Hannum for both cancer risk and cancer survival (including cancer-specific and other-cause deaths). While these inconsistencies in findings for different age acceleration measures are difficult to explain, and may be partly due to small sample sizes in previous studies, the balance of evidence suggests that age acceleration is weakly associated with both risk of, and survival from, at least some cancers. Observed associations with more strongly genetically determined characteristics, such as age at menopause 62 and 
Conclusion
DNA methylation-based measures of age acceleration are associated with increased cancer risk and shorter cancer survival, after adjusting for major cancer risk factors. These findings add to the evidence regarding the use of methylation markers of biological aging as putative predictors of health outcomes and might help to better understand the relationship between aging and cancer. 
